Article Details

Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support ...

Retrieved on: 2022-03-08 00:15:40

Tags for this article:

Click the tags to see associated articles and topics

Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support .... View article details on hiswai:

Excerpt

-First-in-Class Anti-PVR (CD155) Monoclonal Antibody NTX1088 Induces Anti-Tumor Immunity with Unique Triple Mechanism of Action Designed to ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up